The 60% interim readout will likely arrive in the next 3 weeks I reckon.
Judging by@kervio 's great analysis on another thread, we are a reasonable chance to stop at that point, although I'm still very happy to continue to the full 300 patients to gain access to the full data set.
Let's not underestimate the treasure trove of data that will be revealed in the 40 odd secondary endpoints. That data will assist in future trials for years to come.
Pfizer announcement, page-128
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
0.005(0.54%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 93.0¢ | 93.5¢ | 91.5¢ | $1.473M | 1.596M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 32370 | 92.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 93.0¢ | 60258 | 5 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |